Obesity

News Obesity

• Body fat hardens arteries after middle age

  In young people, blood vessels appear to be able to compensate for the effects of obesity. But after middle age, this adaptability is lost, and arteries become progressively stiffer as body fat rises – potentially increasing the risk of dying from cardiovascular disease. The researchers suggest that more

• Novel study reports marijuana users have better blood sugar control

  Regular marijuana use is associated with favorable indices related to diabetic control, say investigators. They found that current marijuana users had significantly lower fasting insulin and were less likely to be insulin resistant, even after excluding patients with a diagnosis of diabetes mellitus more

• Disposable immunosensor for determination of leptin in serum and breast milk

  Scientists in Spain have developed a disposable magnetic bead-based immunosensor to detect the hormone leptin. Leptin helps regulate food intake and is thought to play a role in obesity. This new sensor is very sensitive with a lower limit of detection than current immunoassays. The sensor was succe more

White papers Obesity

• Metagenomics Analysis Using the Genome Sequencer FLX System
  

  The Genome Sequencer FLX System from 454 Life Sciences and Roche Applied Science is a versatile sequencing platform suitable for a wide range of applications, including de novo sequencing and assembly of genomic DNA, transcriptome sequencing, small RNA analysis, and amplicon sequencing. The Genome Sequencer FLX is built upon 454 Sequencing technology that enables long read lengths and very high single-read accuracy. One application in which the technology is accelerating the field's understanding is metagenomics. more

• The New Genome Sequencer FLX System
  

  In 2005, the Genome Sequencer 20 System was introduced into the global life science market. Based on the revolutionary 454 sequencing technology, this system is able to generate hundreds of thousands of sequence reads in a few hours at a fraction of costs compared with the traditional Sanger technology. more

Publications Obesity

• Mosaic Isochromosome 15q and Maternal Uniparental Isodisomy for Chromosome 15 in a Patient With Morbid Obesity and Variant PWS‐Like Phenotype

  Abstract Angelman and Prader–Willi syndromes are reciprocal imprinting disorders caused by loss of maternally or paternally expressed genes, respectively, within 15q11.2–q13. Angelman syndrome (AS; OMIM 105830) is a neurodevelopmental disorder and is due to the loss of maternally expressed UBE3 more

• Descriptive Epidemiology of Idiopathic Clubfoot

  Abstract Clubfoot is a common structural malformation, occurring in approximately 1/1,000 live births. Previous studies of sociodemographic and pregnancy‐related risk factors have been inconsistent, with the exception of the strong male preponderance and association with primiparity. Hypotheses more

• Deletions of 16p11.2 and 19p13.2 in a Family With Intellectual Disability and Generalized Epilepsy

  Abstract Rare copy number variants (CNVs) have been established as an important cause of various neurodevelopmental disorders, including intellectual disability (ID) and epilepsy. In some cases, a second CNV may contribute to a more severe clinical presentation. Here we present two siblings and more

Market studies Obesity

• Peru Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: Based on new historical data for Peru's pharmaceutical sales in 2010 and 2011, we have reevaluated our forecasts for the country. The total market, worth PEN3.90bn (US$1.42bnm) in 2011, is now expected to post a slightly higher five-year compound annual growth rate (CAGR) of 7.6%, as measu more

• South Korea Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: A key theme in the South Korean pharmaceutical market is the government's incessant pharmaceutical price cuts that have created a cloud of uncertainty over the sector. In addition, a price cut announced in August 2011 is set to be effective later in 2012, which will mean an average 17% pri more

• France Pharmaceuticals and Healthcare Report Q4 2012

  BMI View: Aligning with our view that we expect the French government to engage in more concerted fiscal consolidation to mount over the coming quarters, particularly following the elections held in early 2012, we believe that the publication of Mutualité Française's data on the falling volume sales more

Websites Obesity